Abstract

Cultivation of asparagus (Asparagus officinalis L.; Asp) for food and medicinal use has taken place since the early Roman Empire. Today, Asp represents a worldwide diffuse perennial crop. Lower portions of the spears represent a food industry waste product that can be used to extract bioactive molecules. In this study, aqueous extracts derived from the non-edible portion of the plant (hard stem) were prepared and characterized for chemical content. Furthermore, the biocompatibility and bioactivity of Asp aqueous extracts were assessed in vitro on normal fibroblasts and on breast cancer cell lines. Results showed no interference with fibroblast viability, while a remarkable cytostatic concentration-dependent activity, with significant G1/S cell cycle arrest, was specifically observed in breast cancer cells without apoptosis induction. Asp extracts were also shown to significantly inhibit cell migration. Further analyses showed that Asp extracts were characterized by specific pro-oxidant activity against tumoral cells, and, importantly, that their combination with menadione resulted in a significant enhancement of oxidants production with respect to menadione alone in breast cancer cells but not in normal cells. This selectivity of action on tumoral cells, together with the easiness of their preparation, makes the aqueous Asp extracts very attractive for further investigation in breast cancer research, particularly to investigate their role as possible co-adjuvant agents of clinical drug therapies.

Highlights

  • Breast cancer (BC) is the most common cancer among women [1]

  • In recent years, increasing attention has been paid to sustainable recycling of food waste, mainly focusing on recovering bioactive molecules

  • This might represent a new source for drug production [21], especially for fields such as cancer where drug resistance or side effects still cause treatment interruption or failure

Read more

Summary

Introduction

Breast cancer (BC) is the most common cancer among women [1] It is classified mainly based on the expression of three receptors that determine its pharmacological response and, severity: estrogen receptor (ER), progesterone receptor (PgR), and epidermal growth factor receptor 2 (HER2). The majority of cases are hormone-dependent, showing overexpression of ER and PgR [2]. In those patients, endocrine-based treatment is used as a first-line treatment; after its initial efficacy, about 50% of patients develop endocrine resistance and treatment failure, requiring different choices or use of combined therapy [3]. Triple-negative breast cancers (TNBC; ER-, PgR-, HER2-), on the other hand, account for 10–15% of cases and still do not have efficient treatment. Since TNBC show an unfavorable prognosis and hormone-dependent BC has a 5-year survival rate of 25%, it is important to find an efficient and relatively safe cure to improve patients’ survival [4]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call